Specific structural modifications to pepstatin analogues yield compounds with high inhibitory potency against human plasma renin activity in vitro.
Answers are grounded in this paper and cite their sources.
These modifications merit in vivo testing; leaves open whether optimized analogues can advance as renin inhibitors.
Pepstatin analogues corresponding to the general formula A-X-Y-Sta-Ala-Sta-R were synthesized in solution phase. Various changes in the nature of the A, X, and Y groups were made to improve the inhibitory potency against human plasma renin activity. The results were interpreted by use of the active-site model based on the sequence of human angiotensinogen. The tert-butyloxycarbonyl group and the isovaleryl group were found to be the most effective acyl groups (A). The analogues having a Phe residue in place of Val1 (X) and His or amino acid with an aliphatic side chain such as norleucine or norvaline in the Y position showed the highest inhibition of human plasma renin activity with IC50 values of about 10(-8)M. Esterification or amidification of the carboxyl group of the C-terminal statine did not change the inhibitory potency. The selectivity for rat, dog, pig, and monkey plasma renin of the most interesting compounds was studied.
No takes yet. Share an insight, caveat, or question.
Guegan et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: